Blinatumomab治疗复发难治B细胞非霍奇金淋巴瘤的长期结局
该单中心长期随访分析纳入38例参与MT103-104 I期试验的复发难治B细胞非霍奇金淋巴瘤患者,未发现长期毒性尤其无神经认知损害。全体中位总生存期(OS)为4.6年;接受≥60 µg/m2/天且缓解者中位OS达7.7年,6例存活者无治疗超过7年,而低于最大耐受剂量(MTD)者中位OS仅1.1年。
要点
- Blinatumomab未显示长期毒性,尤其无神经认知损害。
- ≥60 µg/m2/天且缓解者中位OS为7.7年,6例无治疗超7年。
- 低于MTD者中位OS仅1.1年,支持60 µg/m2/天为靶剂量。
核心结论
- Blinatumomab缺乏长期毒性,并可能在复发难治B细胞非霍奇金淋巴瘤中诱导持续缓解。
- 60 µg/m2/天似乎代表Blinatumomab在复发难治B细胞非霍奇金淋巴瘤中实现持久缓解所需的靶剂量水平。
研究设计与样本
- 单中心、长期随访分析,纳入38例参与MT103-104 I期剂量递增和扩展试验(NCT00274742)的复发难治B细胞非霍奇金淋巴瘤患者。
主要发现
- 未发现长期毒性证据,尤其无Blinatumomab诱导的神经认知损害。
- 整个研究人群中位总生存期(OS)为4.6年。
- 接受≥60 µg/m2/天且对Blinatumomab有应答的患者中位OS为7.7年。
- 6例在最大耐受剂量(MTD)下治疗的存活患者已无治疗超过7年。
- 接受低于MTD剂量水平治疗的患者中位OS仅为1.1年。
关键数值与推荐
- MT103-104 I期试验定义60 µg/m2/天为最大耐受剂量(MTD)。
- 临床上最相关的不良事件为神经系统症状和细胞因子释放综合征。
临床怎么用
- 对于复发难治B细胞非霍奇金淋巴瘤,Blinatumomab 60 µg/m2/天可能实现持久缓解且无长期毒性。
局限性
- 单中心、长期随访分析,样本量38例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blinatumomab, the first-in-class CD3/CD19 bispecific T-cell engager antibody construct, has recently been approved for treating patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia. However, the clinical proof of concept of blinatumomab efficacy was initially demonstrated in patients with R/R B-cell non-Hodgkin lymphoma (B-NHL) in the MT103-104 phase 1 dose-escalation and expansion trial (NCT00274742), which defined 60 µg/m2 per day as the maximum tolerated dose (MTD). The clinically most relevant adverse effects were neurologic symptoms and cytokine release syndrome. Currently, there are no data on long-term outcomes and toxicity for B-NHL patients receiving blinatumomab treatment, so we performed a single-center, long-term follow-up analysis of 38 patients who participated in the MT103-104 phase 1 trial. We found no evidence for long-term toxicities, especially no blinatumomab-induced neurocognitive impairments. For the entire study population, the median overall survival (OS) was 4.6 years. Remarkably, patients who had received ≥60 µg/m2 per day and responded to blinatumomab achieved a median OS of 7.7 years. Of note, 6 of the surviving patients treated at the MTD have been treatment-free for more than 7 years. In contrast, patients who were treated at dose levels below the MTD had a median OS of only 1.1 years. These results indicate that 60 µg/m2 per day seems to represent the targeted dose level of blinatumomab required for durable remission in R/R B-NHL. Here, we provide the first clinical evidence that blinatumomab lacks long-term toxicity and has the potential to induce sustained remissions in patients with R/R B-NHL.
引用
- Dufner V, Sayehli CM, Chatterjee M, et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019. PMID: 31451445. doi:10.1182/bloodadvances.2019000025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。